CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal

By Akshay Kedari  | Date: 2020-10-12

CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal

Chinese biotechnology company, CStone Pharmaceuticals has recently announced that it has completed the Share Subscription Agreement with Pfizer Inc. for its newly issued shares worth US$200 million. The move furthers the biotech’s multifaceted strategic collaboration with Pfizer which it had announced back in September 2020.

Reportedly, Hong Kong’s Listing Committee Of The Stock Exchange had given a green light for the listing of 115,928,803 additional shares bought at a price of HK$13.37 per share by Pfizer. With this purchase, Pfizer now owns almost a 9.90 percent stake in CStone Pharmaceuticals.

According to reliable sources, CStone’s Share Subscription Agreement comes as a part of the strategic collaboration framework with Pfizer to accelerate its commercial, financial and strategic objectives as it moves to become a fully integrated biopharma firm.

After the completion of this agreement, Pfizer will have an exclusive license to commercialize CStone’s sugemalimab, one of its core late-stage assets in China and an anti-PD-L1 monoclonal antibody. Additionally, Pfizer and CStone would also be able to collaborate on the commercialization and development of additional oncology assets within the Greater China region.

Both the companies will have the option to pursue a selected basis joint in-licensing deal for supplementary oncology assets in the local market. Sources close to the matter cite that Goldman Sachs will act as CStone’s financial advisor, helping it to handle all the necessary transactions. As for legal advisors, Cooley will be representing CStone, and Clifford Chance will be representing Pfizer.

Speaking on the development, Pierre Gaudreault, Acting President, Pfizer China biopharmaceuticals group, said that this partnership builds on its longstanding history with CStone where Pfizer helped the Chinese biotech to develop a potential best-in-class PD-L1 therapy, which Pfizer will commercialize after receiving the required approval.

Besides, this new deal also strengthens its collaboration with a promising pharmaceutical firm that has remarkable clinical development capabilities.

Source Credit: http://www.cstonepharma.com/en/html/news/2470.html

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Hyundai’s U.S. investment expected to reach USD 10 billion by 2025

Hyundai’s U.S. investment expected to reach USD 10 billion by 2025

By Akshay Kedari

South Korea's largest carmaker Hyundai Motor Group is reportedly planning to invest an additional USD 5 billion in the U.S. by 2025. The company aims to strengthen its collaboration with technological firms in the country. During a visit to Se...

Amazon Smart Commerce to digitize 10 million small businesses in India

Amazon Smart Commerce to digitize 10 million small businesses in India

By Akshay Kedari

E-commerce behemoth Amazon Inc. has reportedly launched a “Smart Commerce” initiative in India, aiming to digitalize 10 million small businesses, allow for USD 10 billion worth in exports, and create 2 million jobs by 2025. During the ...

McDonald’s to leave Russia after 30 years amidst Ukraine’s invasion

McDonald’s to leave Russia after 30 years amidst Ukraine’s invasion

By Akshay Kedari

After Ukraine’s invasion, multinational fast-food giant McDonald's Corp. is reportedly planning to sell all its restaurants in Russia, pulling operations from the nation after 30 years. The world's biggest fast-food chain closed 847 ...

Berlin’s GetHenry bags USD 17.4 Mn seed funding for business expansion

Berlin’s GetHenry bags USD 17.4 Mn seed funding for business expansion

By Akshay Kedari

GetHenry, a Berlin-based company that offers couriers and logistics organizations electric last-mile delivery bikes, has reportedly raised USD 17.4 million seed round to grow its operations across Europe. The latest investment round was led by LocalG...

Ferrari to equip the upcoming Purosangue with its trademark V12 engine

Ferrari to equip the upcoming Purosangue with its trademark V12 engine

By Akshay Kedari

Italian luxury sports car manufacturer Ferrari S.p.A. will equip its much-awaited Purosangue SUV with a 12-cylinder engine, as it focused more on fuel-efficient models. Confirming the news, Ferrari Chief Executive Benedetto Vigna claimed that the com...